Literature DB >> 15557590

Transparency in drug regulation: mirage or oasis?

Joel Lexchin1, Barbara Mintzes.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15557590      PMCID： PMC527339          DOI： 10.1503/cmaj.1041446

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  9 in total

1.  Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

Authors:  J M Wright; T L Perry; K L Bassett; G K Chambers
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

2.  Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

Authors:  J B Hrachovec; M Mora
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

Review 3.  Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.

Authors:  Hans Melander; Jane Ahlqvist-Rastad; Gertie Meijer; Björn Beermann
Journal:  BMJ       Date:  2003-05-31

Review 4.  Synthesising licensing data to assess drug safety.

Authors:  Klim McPherson; Elina Hemminki
Journal:  BMJ       Date:  2004-02-28

5.  Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials.

Authors:  E Hemminki; K McPherson
Journal:  BMJ       Date:  1997-07-19

6.  Statement of the International Working Group on transparency and accountability in drug regulation.

Authors: 
Journal:  Int J Risk Saf Med       Date:  1996

7.  Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease.

Authors:  E Hemminki; K McPherson
Journal:  Lancet       Date:  2000-02-12       Impact factor: 79.321

8.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272
  9 in total
  4 in total

1.  Reinstitutionalizing transparency at Health Canada.

Authors:  Matthew Herder
Journal:  CMAJ       Date:  2015-12-22       Impact factor: 8.262

2.  Summary Basis of Decision in context.

Authors:  Diane Gorman
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

3.  Quality and quantity of information in summary basis of decision documents issued by health Canada.

Authors:  Roojin Habibi; Joel Lexchin
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

4.  Lack of proportionality. Seven specifications of public interest that override post-approval commercial interests on limited access to clinical data.

Authors:  Daniel Strech; Jasper Littmann
Journal:  Trials       Date:  2012-07-02       Impact factor: 2.279
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.